---
figid: PMC8066213__diagnostics-11-00640-g001
figtitle: Inhibition of vascular endothelial growth factor (VEGF)/vascular endothelial
  growth factor receptor (VEGFR) signaling
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Avena sativa
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC8066213
filename: diagnostics-11-00640-g001.jpg
figlink: pmc/articles/PMC8066213/figure/diagnostics-11-00640-f001/
number: F1
caption: Inhibition of vascular endothelial growth factor (VEGF)/vascular endothelial
  growth factor receptor (VEGFR) signaling. Numerous strategies exist to inhibit VEGF/VEGFR
  signaling. VEGF can be blocked by monoclonal antibodies (mAbs) (bevacizumab) or
  by fusion proteins (aflibercept). Its receptor, VEGFR, can be targeted by fully
  humanized monoclonal antibodies (ramucirumab). The receptor can also be targeted
  for its intracellular tyrosine kinase activity (tyrosine kinase inhibitors, TKIs).
  Finally, one strategy consists of inhibiting the downstream signaling pathways of
  VEGFR by targeting either the Raf (Rapidly Accelerated Fibrosarcoma)/mitogen-activated
  protein kinase (MAPK)/ERK (Extracellular signal-Regulated Kinase) pathway with B-Raf
  inhibitors (dabrafenib, vemurafenib), or the endothelial nitric oxide synthase (eNOS)
  pathway (dasatinib, ponatinib) or the mammalian target of rapamycin (mTOR) pathway
  (everolimus, temsirolimus, ridaforolimus).
papertitle: Nephrotoxicity of Anti-Angiogenic Therapies.
reftext: Margaux Van Wynsberghe, et al. Diagnostics (Basel). 2021 Apr;11(4):640.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9415235
figid_alias: PMC8066213__F1
figtype: Figure
redirect_from: /figures/PMC8066213__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8066213__diagnostics-11-00640-g001.html
  '@type': Dataset
  description: Inhibition of vascular endothelial growth factor (VEGF)/vascular endothelial
    growth factor receptor (VEGFR) signaling. Numerous strategies exist to inhibit
    VEGF/VEGFR signaling. VEGF can be blocked by monoclonal antibodies (mAbs) (bevacizumab)
    or by fusion proteins (aflibercept). Its receptor, VEGFR, can be targeted by fully
    humanized monoclonal antibodies (ramucirumab). The receptor can also be targeted
    for its intracellular tyrosine kinase activity (tyrosine kinase inhibitors, TKIs).
    Finally, one strategy consists of inhibiting the downstream signaling pathways
    of VEGFR by targeting either the Raf (Rapidly Accelerated Fibrosarcoma)/mitogen-activated
    protein kinase (MAPK)/ERK (Extracellular signal-Regulated Kinase) pathway with
    B-Raf inhibitors (dabrafenib, vemurafenib), or the endothelial nitric oxide synthase
    (eNOS) pathway (dasatinib, ponatinib) or the mammalian target of rapamycin (mTOR)
    pathway (everolimus, temsirolimus, ridaforolimus).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - KDR
  - FLT1
  - FLT4
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - EPHB2
  - NOS3
  - ENO4
  - MTOR
  - Vegfa
  - Zhx2
  - Ephb2
  - Mapk1
  - Nos3
  - Mtor
  - Braf
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - MKP-4
  - p38b
  - rl
  - Raf
  - Erk7
  - Tor
  - Tyrosine
  - Axitinib
  - Sunitinib
  - Sorafenib
  - Vemurafenib
  - Dabrafenib
  - Dasatinib
  - Ponatinib
  - Everolimus
  - Temsirolimus
  - Ridaforolimus
---
